1. Home > Latest Topics >

Question 14: Merits of post-marketing surveillance data

20 June, 2018

Question 14
Levofloxacin has an extensive post-marketing database showing exceptional safety in > 250 million prescriptions. Could you discuss the merits of the post-marketing surveillance (PMS) data, and do any other comparator agents have such well-documented safety records?


LATEST TOPICS

Managing Infectious Diseases in Emergency Medicine: A Specialist’s Approach
10 April, 2024
Advancing standardised diagnosis and treatment of acute infectious disease: Insights from an expert in theory–technique integration
08 April, 2024
Managing severe infections: Practical approaches for antibiotic use, including combination therapy
05 March, 2024
Updating Traditional Approaches: Expert Insights on Addressing Urinary Tract Infections
26 February, 2024
Antibiotic resistance may be driven by diverse factors, including extreme climatic events
14 February, 2024

RELATED ARTICLES

Antimicrobial resistance in respiratory tract infections: Current trends and strategies
06 August, 2021
Could fluoroquinolones play a role in treating ceftriaxone-resistant bacterial UTI?
19 October, 2023
Under the new medical reform, there are challenges for the rational use of antibiotics, making it necessary to adopt coping strategies
20 April, 2023
Managing Urinary Tract Infection: Treatment Strategies in Japan
20 July, 2022
Lower Respiratory Tract Infections: AECOPD, Aspiration, and Pneumonia in the COVID-19 Era (Chapter 1)
24 November, 2022